 |
Перспективные направления исследований.
|
|
|
|
Низкое качество доказательности изложенных рекомендаций связано с ограниченностью данных связывающих диагностические стратегии с лечебными результатами. Этот феномен связан с редкостью заболевания и отсутствием унифицированности диагностических методов. В дополнение к этому, публикуемые данные больших территориальных референсных центров, основанные на диагностике большого числа создает впечатление о большей распространенности заболевания и простоте его диагностики. Эти проблемы выдвигают на первый план потребность в дальнейшем исследовании диагностических критериев гиперкортицизма. Предлагаемые направления работы могут улучшить результаты лечения больных гиперкортицизмом:
1. Объединение информации. Создание национальными и международными эндокринными организациями базы данных пациентов, проверенных на синдром Кушинга, учитывая предполагаемое объединение диагностической информации. Эта объединенная информация помогла бы определить дифференциально-диагностические признаки и обосновать точные стратегии тестирования.
2. Стандартизация исследований. Диагноз синдрома Кушинга критически зависит от качества лабораторной диагностики кортизола в биожидкостях RIA, ELISA, или LC-MS/MS. Клиницисты нуждаются в большей специфичности методов, точности публикуемых диагностических критериев (cut-off). Национальные референсные лаборатории должны использоваться в трудных случаях.
3. Улучшенные качества клинических данных и проспективные клинические исследования. Первичная диагностика гиперкортицизма должна отвечать конечной цели любой диагностики - оказывать положительное влияние на лечебные результаты. Необходимо изучение результатов лечения, проведенного по современным лечебным стратегиям. В частности, существуют противоречия о необходимости оперативного лечения синдрома субклинического гиперкортицизма, выявленного у больных с инциденталомой надпочечника. Необходимо выполнение рандомизированных клинических испытаний, для выработки оптимальной лечебной тактики.
|
|
|
Литература:
1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y,Flottorp S, Guyatt GH, Harbour RT, Haugh MC, HenryD, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N,
Mason J, Middleton P, Mrukowicz J, O’Connell D,Oxman AD, Phillips B, Schunemann HJ, Edejer TT,Varonen H, Vist GE, Williams Jr JW, Zaza S 2004 Grading quality of evidence and strength ofrecommendations. BMJ 328:1490
2. Elamin MB, Murad MH, Mullan R, Erickson D, HarrisK, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553–1562
3. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical
practice guidelines in endocrinology using the GRADE system. J Clin Endocrinol Metab 93:666–673
4. Etxabe J, Vazquez JA 1994 Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479–484
5. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J 2001 Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86:117–123
6. Nugent CA, Warner HR, Dunn JT, Tyler FH 1964 Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 24:621–627
7. Pecori Giraldi F, Pivonello R, Ambrogio AG, De Martino MC, De Martin M, Scacchi M, Colao A, Toja PM, Lombardi G, Cavagnini F 2007 The dexamethasonesup ressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. Clin Endocrinol (Oxf) 66:251–257
8. Ross EJ, Linch DC 1982 Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 2:646–649
9. Yanovski JA, Cutler GB, Jr., Chrousos GP, Nieman LK 1993 Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A
new test to distinguish Cushing’s syndrome from pseudo- Cushing’s states. JAMA 269:2232–2238
10. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W, et al 1986 Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. Pathophysiologic and diagnostic implications. N Engl J Med 314:1329–1335
11. Cushing H 1932 The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 50:137–195
|
|
|
12. Plotz CM, Knowlton AI, Ragan C 1952 The natural history of Cushing’s syndrome. Am J Med 13:597–614
13. Swearingen B, Biller BM, Barker 2nd FG, Katznelson L, Grinspoon S, Klibanski A, Zervas NT 1999 Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130:821–824
14. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G 1999 Persistence of increased cardiovascular
risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84:2664–2672
15. Wei L, MacDonald TM, Walker BR 2004 Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764–770
16. Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, Lesage J, Lafontaine L, Lacroix A 2002 Loss of brain volume in endogenous Cushing’s syndrome and
its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87:1949–1954
17. Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW 1995 Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865
18. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK 2006 Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical
remission. J Clin Endocrinol Metab 91:447–453
19. Sarlis NJ, Chanock SJ, Nieman LK 2000 Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 85:42–47
20. Reincke M 2000 Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 29:43–56
21. Terzolo M, Reimondo G, Bovio S, Angeli A 2004 Subclinical Cushing’s syndrome. Pituitary 7:217–223
22. Tsagarakis S, Vassiliadi D, Thalassinos N 2006 Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 29:471–482
23. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH, 3rd, Nwariaku FE 2007 “Subclinical Cushing’s syndrome” is not subclinical: improvement after
adrenalectomy in 9 patients. Surgery 142:900–905
24. Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB, Savage MO 2005 Final adult height and body mass index after cure
of paediatric Cushing’s disease. Clin Endocrinol (Oxf) 62:466–472
25. Storr HL, Mitchell H, Swords FM, Main KM, Hindmarsh PC, Betts PR, Shaw NJ, Johnston DI, Clark AJ, Reznek RH, Grossman AB, Savage MO 2004 Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing’s syndrome due to primary nodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 61:553–559
26. Magiakou MA, Mastorakos G, Chrousos GP 1994 Final stature in patients with endogenous Cushing’s syndrome. J Clin Endocrinol Metab 79:1082–1085
27. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA 2005 Iatrogenic Cushing’s syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 90:4394–4398
28. Baid SK, Sinaii N, Wade M, Rubino D, Nieman LK 2007 Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism. J Clin Endocrinol Metab 92:3102–3107
29. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M 1997 Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 157:1651–1656
30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120:e575–e586
31. Bulow B, Jansson S, Juhlin C, Steen L, Thoren M, Wahrenberg H, Valdemarsson S, Wangberg B, Ahren B 2006 Adrenal incidentaloma—follow-up results from a
|
|
|
Swedish prospective study. Eur J Endocrinol 154:419–423
32. Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B 2002 Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol
147:489–494
33. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, Gin H, Roger P, Tabarin A 2003 Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 88:5808–5813
34. Reimondo G, Pia A, Allasino B, Tassone F, Bovio S, Borretta G, Angeli A, Terzolo M 2007 Screening of Cushing’s syndrome in adult patients with newly diagnosed
diabetes mellitus. Clin Endocrinol (Oxf) 67:225–229
35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for
Cushing’s syndrome in the obese. Obes Res 10:1217–1221
36. Anderson Jr GH, Blakeman N, Streeten DH 1994 The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12:609–615
37. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T 2004 Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a
general outpatient clinic in Japan. Hypertens Res 27:193–202
38. Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, Santini SA, Guglielmi G, Carnevale V, Scillitani A 2007 Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 147:541–548
39. Klose M, Lange M, Rasmussen AK, Skakkebaek NE, Hilsted L, Haug E, Andersen M, Feldt-Rasmussen U 2007 Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab 92:1326–1333
40. Findling JW, Pinkstaff SM, Shaker JL, Raff H, Nelson JC 1998 Pseudohypercortisoluria: spurious elevation of urinary cortisol due to carbamazepine. Endocrinologist 8:51–54
41. Meikle AW, Findling J, Kushnir MM, Rockwood AL, Nelson GJ, Terry AH 2003 Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol
assayed by high-performance liquid chromatography. J Clin Endocrinol Metab 88:3521–3524
42. Lin CL, Wu TJ, Machacek DA, Jiang NS, Kao PC 1997 Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of
Cushing’s syndrome. J Clin Endocrinol Metab 82:151–155
43. Turpeinen U, Markkanen H, Valimaki M, Stenman UH 1997 Determination of urinary free cortisol by HPLC. Clin Chem 43:1386–1391
44. Nickelsen T, Lissner W, Schoffling K 1989 The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol 94:275–280
45. Qureshi AC, Bahri A, Breen LA, Barnes SC, Powrie JK, Thomas SM, Carroll PV 2007 The influence of the route of oestrogen administration on serum levels of cortisolbinding globulin and total cortisol. Clin Endocrinol (Oxf) 66:632–635
46. Hamrahian AH, Oseni TS, Arafah BM 2004 Measurements of serum free cortisol in critically ill patients. N Engl J Med 350:1629–1638
47. Kyriazopoulou V, Vagenakis AG 1992 Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. J Clin Endocrinol Metab 75:315–317
48. Meikle AW 1982 Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol (Oxf) 16:401–408
|
|
|
49. Crapo L 1979 Cushing’s syndrome: a review of diagnostic tests. Metabolism 28:955–977
50. Melby JC 1971 Assessment of adrenocortical function. N Engl J Med 285:735–739
51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F 2007 Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment
in a large series. J Clin Endocrinol Metab 92:4123–4129
52. Mericq MV, Cutler Jr GB 1998 High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab 83:682–684
53. Chan KC, Lit LC, Law EL, Tai MH, Yung CU, Chan MH, Lam CW 2004 Diminished urinary free cortisol excretion in patients with moderate and severe renal
impairment. Clin Chem 50:757–759
54. Kidambi S, Raff H, Findling JW 2007 Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur J Endocrinol 157:725–731
55. Krieger DT, Allen W, Rizzo F, Krieger HP 1971 Characterization of the normal temporal pattern of plasma corticosteroid levels. J Clin Endocrinol Metab 32:266–284
56. Glass AR, Zavadil 3rd AP, Halberg F, Cornelissen G, Schaaf M 1984 Circadian rhythm of serum cortisol in Cushing’s disease. J Clin Endocrinol Metab 59:161–165
57. Refetoff S, Van Cauter E, Fang VS, Laderman C, Graybeal ML, Landau RL 1985 The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing’s syndrome. J Clin Endocrinol Metab 60:527–535
58. Read GF, Walker RF, Wilson DW, Griffiths K 1990 Steroid analysis in saliva for the assessment of endocrine function. Ann NY Acad Sci 595:260–274
59. Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC 1999 Out-patient screening for Cushing’s syndrome: the sensitivity of the combination of circadian rhythm and
overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 84:878–882
60. Laudat MH, Cerdas S, Fournier C, Guiban D, Guilhaume B, Luton JP 1988 Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function.
J Clin Endocrinol Metab 66:343–348
61. Luthold WW, Marcondes JA, Wajchenberg BL 1985 Salivary cortisol for the evaluation of Cushing’s syndrome. Clin Chim Acta 151:33–39
62. Papanicolaou DA, Mullen N, Kyrou I, Nieman LK 2002 Nighttime salivary cortisol: a useful test for the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab
87:4515–4521
63. Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F 2003 Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 88:4153–4157
64. Raff H, Raff JL, Findling JW 1998 Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 83:2681–2686
65. Trilck M, Flitsch J, Ludecke DK, Jung R, Petersenn S 2005 Salivary cortisol measurement—a reliable method for the diagnosis of Cushing’s syndrome. Exp Clin Endocrinol Diabetes 113:225–230
66. Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Muller B 2005 Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 90:5730–5736
67. Yaneva M, Mosnier-Pudar H, Dugue MA, Grabar S, Fulla Y, Bertagna X 2004 Midnight salivary cortisol for the initial diagnosis of Cushing’s syndrome of various causes. J Clin Endocrinol Metab 89:3345–3351
68. Martinelli Jr CE, Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC 1999 Salivary cortisol for screening of Cushing’s syndrome in children. Clin Endocrinol (Oxf) 51:67–71
69. Butler PW, Besser GM 1968 Pituitary-adrenal function in severe depressive illness. Lancet 1:1234–1236
70. Pfohl B, Sherman B, Schlechte J, Stone R 1985 Pituitaryadrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 42:897–903
71. Ross RJ, Miell JP, Holly JM, Maheshwari H, Norman M, Abdulla AF, Buchanan CR 1991 Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in
intensive care patients. Clin Endocrinol (Oxf) 35:361–367
72. Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E 2005 Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 63:642–649
73. Dorn LD, Lucke JF, Loucks TL, Berga SL 2007 Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann Clin Biochem 44:281–284
74. Poll EM, Kreitschmann-Andermahr I, Langejuergen Y, Stanzel S, Gilsbach JM, Gressner A, Yagmur E 2007 Saliva collection method affects predictability of serum
|
|
|
cortisol. Clin Chim Acta 382:15–19
75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fukushima K, Krozowski ZS 1996 Localization of 11&bgr;-hydroxysteroid dehydrogenase type
II in human epithelial tissues. J Clin Endocrinol Metab 81:3244–3248
76. Badrick E, Kirschbaum C, Kumari M 2007 The relationship between smoking status and cortisol secretion. J Clin Endocrinol Metab 92:819–824
77. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA 2004 Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. Horm Behav 46:39–46
78. Newell-Price J, Trainer P, Besser M, Grossman A 1998 The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing's states. Endocr Rev 19:647–672
79. Cronin C, Igoe D, Duffy MJ, Cunningham SK, McKenna TJ 1990 The overnight dexamethasone test is a worthwhile screening procedure. Clin Endocrinol (Oxf) 33:27–33
80. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F 1999 Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84:440–448
81. Findling JW, Raff H, Aron DC 2004 The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metab 89:1222–1226
82. Gorges R, Knappe G, Gerl H, Ventz M, Stahl F 1999 Diagnosis of Cushing’s syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose
dexamethasone suppression test in a large patient group. J Endocrinol Invest 22:241–249
83. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B 1997 Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome-recommendations or a protocol for biochemistry laboratories. Ann Clin Biochem 34(Pt 3):222–229
84. Khan A, Ciraulo DA, Nelson WH, Becker JT, Nies A, Jaffe JH 1984 Dexamethasone suppression test in recently detoxified alcoholics: clinical implications. J Clin Psychopharmacol 4:94–97
85. Liddle GW 1960 Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 20:1539–1560
86. Kennedy L, Atkinson AB, Johnston H, Sheridan B, Hadden DR 1984 Serum cortisol concentrations during low dose dexamethasone suppression test to screen for
Cushing’s syndrome. Br Med J (Clin Res Ed) 289:1188–1191
87. Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler Jr GB, Nieman LK, Chrousos GP 1994 Cushing’s syndrome in children and adolescents.
Presentation, diagnosis, and therapy. N Engl J Med 331:629–636
88. Erickson D, Natt N, Nippoldt T, Young Jr WF, Carpenter PC, Petterson T, Christianson T 2007 Dexamethasonesuppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. J Clin Endocrinol Metab 92:2972–2976
89. Gatta B, Chabre O, Cortet C, Martinie M, Corcuff JB, Roger P, Tabarin A 2007 Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild Cushing’s disease from pseudo-Cushing’s syndrome. J Clin Endocrinol Metab 92:4290–4293
90. Martin NM, Dhillo WS, Banerjee A, Abdulali A, Jayasena CN, Donaldson M, Todd JF, Meeran K 2006 Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 91:2582–2586
91. Nieman L 2007 The dexamethasone-suppressed corticotropin-releasing hormone test for the diagnosis of Cushing’s syndrome: what have we learned in 14 years? J Clin Endocrinol Metab 92:2876–2878 (Editorial)
92. Yanovski JA, Cutler Jr GB, Chrousos GP, Nieman LK 1998 The dexamethasone-suppressed corticotropinreleasing hormone stimulation test differentiates mild
Cushing’s disease from normal physiology. J Clin Endocrinol Metab 83:348–352
93. Meinardi JR, Wolffenbuttel BH, Dullaart RP 2007 Cyclic Cushing’s syndrome: a clinical challenge. Eur J Endocrinol 157:245–254
94. Yanovski J, Cutler Jr BG, Chrousos GB, Nieman LK Prospective evaluation of the dexamethasone-suppressed corticotropin-releasing hormone test in the differential
diagnosis of Cushing syndrome and pseudo-Cushing states. Program of the 77th Annual Meeting of The Endocrine Society, Washington, DC, 1995, p 99 (Abstract OR39-2)
95. Nieman LK, Cutler Jr GB, Oldfield EH, Loriaux DL, Chrousos GP 1989 The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human
CRH stimulation test for the diagnosis of Cushing’s disease. J Clin Endocrinol Metab 69:165–169
96. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M 1995 A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxf) 43:545–550
97. Ma RC, Chan WB, So WY, Tong PC, Chan JC, Chow CC 2005 Carbamazepine and false positive dexamethasone suppression tests for Cushing’s syndrome. BMJ 330:299–300
98. Papanicolaou DA, Yanovski JA, Cutler Jr GB, Chrousos GP, Nieman LK 1998 A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from
pseudo-Cushing states. J Clin Endocrinol Metab 83:1163–1167
99. Pikkarainen L, Alfthan H, Markkanen H, Sane T 2002 Midnight serum cortisol: comparison of healthy volunteers and hospitalized patients with Cushing’s syndrome. Scand J Clin Lab Invest 62:357–360
100. Putignano P, Bertolini M, Losa M, Cavagnini F 2003 Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome. J Endocrinol Invest 26:539–544
101. Reimondo G, Allasino B, Bovio S, Paccotti P, Angeli A, Terzolo M 2005 Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing’s syndrome. Eur J Endocrinol 153:803–809
102. Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F 2000 The desmopressin test in the differential diagnosis between Cushing’s disease and pseudo-Cushing states. J Clin Endocrinol Metab 85:3569–3574
103. Carr BR, Parker Jr CR, Madden JD, MacDonald PC, Porter JC 1981 Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am
J Obstet Gynecol 139:416–422
104. Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK 2005 Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90:3077–3083
105. Lindsay JR, Nieman LK 2005 The hypothalamicpituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 26:775–799
106. Wallace EZ, Rosman P, Toshav N, Sacerdote A, Balthazar A 1980 Pituitary-adrenocortical function in chronic renal failure: studies of episodic secretion of cortisol and dexamethasone suppressibility. J Clin Endocrinol Metab 50:46–51
107. Oguz Y, Oktenli C, Ozata M, Ozgurtas T, Sanisoglu Y, Yenicesu M, Vural A, Bulucu F, Kocar IH 2003 The midnight-to-morning urinary cortisol increment method is
not reliable for the assessment of hypothalamic-pituitaryadrenal insufficiency in patients with end-stage kidney disease. J Endocrinol Invest 26:609–615
108. Ramirez G, Gomez-Sanchez C, Meikle WA, Jubiz W 1982 Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med 142:1448–1452
109. Workman RJ, Vaughn WK, Stone WJ 1986 Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 63:741–746
|
|
|
